Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPK-88003 Dose Escalation in Type 2 Diabetes
NCT03406377Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegapamodutide in type 2 diabetes mellitus (T2DM), sponsored by OPKO Health. Started Apr 2018; status: completed.
02
Drugs
pegapamodutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03406377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406377.